+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-10-30Number of Pages: 205

Rheumatology Therapeutics Market (Drug Class - Disease Modifying Anti-rheumatic Drugs (DMARD’s), Nonsteroidal Anti-inflammatory Drugs (NSAID’s), Corticosteroids, and Uric Acid Drugs; Disease Indication - Rheumatoid Arthritis, Osteoarthritis, Gout, Psoriatic Arthritis, and Ankylosing Spondylitis; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025

Chapter 1. Preface
1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Rheumatology Therapeutics  market

Chapter 4. Market Overview
4.1. Introduction
            4.1.1. Key Industry Developments
            4.1.2. Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
            4.1.3. Global Rheumatology Therapeutics Market Outlook

Chapter 5. Market Dynamics
     5.1. Drivers
     5.2. Restraints
     5.3. Opportunities
     5.4. Porter’s five forces analysis

Chapter 6. Rheumatology Therapeutics Market Analysis and Forecast, by Drug Class
     6.1. Key Findings
     6.2. Introduction
     6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            6.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     6.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     6.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            6.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            6.3.3. Corticosteroids
            6.3.4. Uric Acid Drugs
            6.3.5. Others
     6.4. Market Attractiveness Analysis, by Drug Class
     6.5. Key Trends

Chapter 7. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Disease Indication
     7.1. Key Findings
     7.2. Introduction
     7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            7.3.1. Rheumatoid Arthritis
            7.3.2. Osteoarthritis
            7.3.3. Gout
            7.3.4. Psoriatic Arthritis
            7.3.5. Ankylosing Spondylitis
            7.3.6.  Others
     7.4. Market Attractiveness Analysis, by Disease Indication
     7.5. Key Trends

Chapter 8. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Route of Administration
     8.1. Key Findings
     8.2. Introduction
     8.3. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            8.3.1. Parenteral
            8.3.2. Oral
            8.3.3. Topical
     8.4. Market Attractiveness Analysis, by Route of Administration
     8.5. Key Trends

Chapter 9. Global Rheumatology Therapeutics Market  Analysis and Forecasts, by Distribution Channel
     9.1. Key Findings
     9.2. Introduction
     9.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            9.3.1. Hospital Pharmacy
            9.3.2. Retail Pharmacy
            9.3.3. Online Pharmacy
     9.4. Market Attractiveness Analysis, by Distribution Channel
     9.5. Key Trends

Chapter 10. Global Rheumatology Therapeutics market  Analysis and Forecasts, by Region
     10.1. Key Findings
     10.2.   Global Market Scenario
     10.3.   Market Value (US$ Mn) Forecast, by Region, 2017-2025
            10.3.1. North America
            10.3.2. Europe
            10.3.3. Asia Pacific
            10.3.4. Latin America
            10.3.5. Middle East & Africa
     10.4. Market Attractiveness Analysis, by Region

Chapter 11. North America Rheumatology Therapeutics market  Analysis and Forecast
     11.1. Key Findings
     11.2. Market size  (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
            11.2.1. U.S.
            11.2.2. Canada
     11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            11.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     11.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     11.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            11.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            11.3.3. Corticosteroids
            11.3.4. Uric Acid Drugs
            11.3.5. Others
     11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            11.4.1. Rheumatoid Arthritis
            11.4.2. Osteoarthritis
            11.4.3. Gout
            11.4.4. Psoriatic Arthritis
            11.4.5. Ankylosing Spondylitis
            11.4.6.  Others
     11.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            11.5.1. Parenteral
            11.5.2. Oral
            11.5.3. Topical
     11.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            11.6.1. Hospital Pharmacy
            11.6.2. Retail Pharmacy
            11.6.3. Online Pharmacy
     11.7. Market Attractiveness Analysis
            11.7.1. By Country/Sub-region
            11.7.2. By Drug Class
            11.7.3. By Disease Indication
            11.7.4. By Route of Administration
            11.7.5. By Distribution Channel
     11.8. Key Trends

Chapter 12. Europe Rheumatology Therapeutics market  Analysis and Forecast
     12.1. Key Findings
     12.2. Market size (US$ Mn) Forecast By Country, 2017-2025
            12.2.1. Germany
            12.2.2. U.K.
            12.2.3. France
            12.2.4. Italy
            12.2.5. Spain
            12.2.6. Russia
            12.2.7. Rest of Europe
     12.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            12.3.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     12.3.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     12.3.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            12.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            12.3.3. Corticosteroids
            12.3.4. Uric Acid Drugs
            12.3.5. Others
     12.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            12.4.1. Rheumatoid Arthritis
            12.4.2. Osteoarthritis
            12.4.3. Gout
            12.4.4. Psoriatic Arthritis
            12.4.5. Ankylosing Spondylitis
            12.4.6.  Others
     12.5. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            12.5.1. Parenteral
            12.5.2. Oral
            12.5.3. Topical
     12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            12.6.1. Hospital Pharmacy
            12.6.2. Retail Pharmacy
            12.6.3. Online Pharmacy
     12.7. Market Attractiveness Analysis
            12.7.1. By Country/Sub-region
            12.7.2. By Drug Class
            12.7.3. By Disease Indication
            12.7.4. By Route of Administration
            12.7.5. By Distribution Channel
     12.8. Key Trends

Chapter 13. Asia Pacific Rheumatology Therapeutics market Analysis and Forecast
     13.1. Key Findings / Developments
     13.2. Market Overview
     13.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
            13.3.1. China
            13.3.2. India
            13.3.3. Japan
            13.3.4. Australia & New Zealand
            13.3.5. Rest of Asia Pacific
     13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            13.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     13.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     13.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            13.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            13.4.3. Corticosteroids
            13.4.4. Uric Acid Drugs
            13.4.5. Others
     13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            13.5.1. Rheumatoid Arthritis
            13.5.2. Osteoarthritis
            13.5.3. Gout
            13.5.4. Psoriatic Arthritis
            13.5.5. Ankylosing Spondylitis
            13.5.6.  Others
     13.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            13.6.1. Parenteral
            13.6.2. Oral
            13.6.3. Topical
     13.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            13.7.1. Hospital Pharmacy
            13.7.2. Retail Pharmacy
            13.7.3. Online Pharmacy
     13.8. Market Attractiveness Analysis
            13.8.1. By Country/Sub-region
            13.8.2. By Drug Class
            13.8.3. By Disease Indication
            13.8.4. By Route of Administration
            13.8.5. By Distribution Channel
     13.9. Key Trends

Chapter 14. Latin America Rheumatology Therapeutics market Analysis and Forecast
     14.1. Key Findings / Developments
     14.2. Market Overview
     14.3. Market Size (US$ Mn) Forecast, by Country, 2017-2025
            14.3.1. Brazil
            14.3.2. Mexico
            14.3.3. Rest of Latin America
     14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            14.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     14.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     14.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            14.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            14.4.3. Corticosteroids
            14.4.4. Uric Acid Drugs
            14.4.5. Others
     14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            14.5.1. Rheumatoid Arthritis
            14.5.2. Osteoarthritis
            14.5.3. Gout
            14.5.4. Psoriatic Arthritis
            14.5.5. Ankylosing Spondylitis
            14.5.6.  Others
     14.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            14.6.1. Parenteral
            14.6.2. Oral
            14.6.3. Topical
     14.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            14.7.1. Hospital Pharmacy
            14.7.2. Retail Pharmacy
            14.7.3. Online Pharmacy
     14.8. Market Attractiveness Analysis
            14.8.1. By Country/Sub-region
            14.8.2. By Drug Class
            14.8.3. By Disease Indication
            14.8.4. By Route of Administration
            14.8.5. By Distribution Channel
     14.9. Key Trends

Chapter 15. Middle East and Africa Rheumatology Therapeutics market Analysis and Forecast
     15.1. Key Findings / Developments
     15.2. Market Overview
     15.3. Market size (US$ Mn) Forecast, by Country, 2017-2025
            15.3.1. GCC Countries
            15.3.2. South Africa
            15.3.3. Israel
            15.3.4. Rest of Middle East and Africa
     15.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2025
            15.4.1. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                     15.4.1.1. Synthetic Disease Modifying Anti-rheumatic Drugs
                     15.4.1.2. Biologic Disease Modifying Anti-rheumatic Drugs
            15.4.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
            15.4.3. Corticosteroids
            15.4.4. Uric Acid Drugs
            15.4.5. Others
     15.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2025
            15.5.1. Rheumatoid Arthritis
            15.5.2. Osteoarthritis
            15.5.3. Gout
            15.5.4. Psoriatic Arthritis
            15.5.5. Ankylosing Spondylitis
            15.5.6.  Others
     15.6. Market size (US$ Mn) Forecast by Route of Administration, 2017-2025
            15.6.1. Parenteral
            15.6.2. Oral
            15.6.3. Topical
     15.7. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2025
            15.7.1. Hospital Pharmacy
            15.7.2. Retail Pharmacy
            15.7.3. Online Pharmacy
     15.8. Market Attractiveness Analysis
            15.8.1. By Country/Sub-region
            15.8.2. By Drug Class
            15.8.3. By Disease Indication
            15.8.4. By Route of Administration
            15.8.5. By Distribution Channel
     15.9. Key Trends

Chapter 16. Competition Landscape
     16.1. Global rheumatology therapeutics Market Share, by Company, 2016
     16.2. Market Player – Competition Matrix (By Tier and Size of companies)
     16.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            16.3.1. Amgen, Inc.
                     16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.1.2. Product Portfolio
                     16.3.1.3. SWOT Analysis
                     16.3.1.4. Strategic Overview
            16.3.2. AbbVie, Inc.
                     16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.2.2. Product Portfolio
                     16.3.2.3. SWOT Analysis
                     16.3.2.4. Strategic Overview
            16.3.3. Pfizer, Inc.
                     16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.3.2. Product Portfolio
                     16.3.3.3. SWOT Analysis
                     16.3.3.4. Financial Overview
                     16.3.3.5. Strategic Overview
            16.3.4. Janssen Biotech, Inc. (Johnson & Johnson)
                     16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.4.2. Product Portfolio
                     16.3.4.3. SWOT Analysis
                     16.3.4.4. Financial Overview
                     16.3.4.5. Strategic Overview
            16.3.5. Novartis AG
                     16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.5.2. Product Portfolio
                     16.3.5.3. SWOT Analysis
                     16.3.5.4. Financial Overview
                     16.3.5.5. Strategic Overview
            16.3.6. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)
                     16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.6.2. Product Portfolio
                     16.3.6.3. SWOT Analysis
                     16.3.6.4. Financial Overview
                     16.3.6.5. Strategic Overview
            16.3.7. Bristol-Myers Squibb Company
                     16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.7.2. Product Portfolio
                     16.3.7.3. SWOT Analysis
                     16.3.7.4. Financial Overview
                     16.3.7.5. Strategic Overview
            16.3.8. Merck & Co., Inc.
                     16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.8.2. Product Portfolio
                     16.3.8.3. SWOT Analysis
                     16.3.8.4. Financial Overview
                     16.3.8.5. Strategic Overview
            16.3.9. Sanofi
                     16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.9.2. Product Portfolio
                     16.3.9.3. SWOT Analysis
                     16.3.9.4. Financial Overview
                     16.3.9.5. Strategic Overview
            16.3.10. Takeda Pharmaceutical
                     16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                     16.3.10.2. Product Portfolio
                     16.3.10.3. SWOT Analysis
                     16.3.10.4. Financial Overview
                     16.3.10.5. Strategic Overview

 

List of Figures

Figure 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, by Drug Class (2016)
Figure 03: Market Value Share, by Disease Indication (2016)
Figure 04: Market Value Share, by Route of Administration (2016)
Figure 05: Market Value Share, by Distribution Channel (2016)
Figure 06: Market Value Share, by Region (2016)
Figure 07: Global Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 08: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Figure 09: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2015–2025
Figure 10: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2015–2025
Figure 11: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Uric Acid Drugs, 2015–2025
Figure 12: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
Figure 13: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 14: Global Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 15: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Rheumatoid Arthritis, 2015–2025
Figure 16: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Osteoarthritis, 2015–2025
Figure 17: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Gout, 2015–2025
Figure 18: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Psoriatic Arthritis, 2015–2025
Figure 19: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Ankylosing Spondylitis, 2015–2025
Figure 20: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2015–2025
Figure 21: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 22: Global Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 23: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oral, 2015-2025
Figure 24: Global rheumatology therapeutics market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Parenteral, 2015–2025
Figure 25: Global Rheumatology Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Topical, 2015-2025
Figure 26: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 27: Global Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 28: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 29: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Figure 30: Global Rheumatology Therapeutics Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2025
Figure 31: Global Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 32: Global rheumatology therapeutics Market Value Share Analysis, by Region, 2017 and 2025
Figure 33: Global rheumatology therapeutics Market Attractiveness Analysis, by Region, 2017-2025
Figure 34: North America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 35: North America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 36: North America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 37: North America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 38: North America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 39: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 40: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 41: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 42: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 43: North America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 44: Europe Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 45: Europe Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 46: Europe Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 47: Europe Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 48: Europe Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 49: Europe Rheumatology Therapeutics Market Attractiveness analysis, by Country/Sub-region, 2017–2025
Figure 50: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 51: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 52: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 53: Europe Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 54: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 55: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 56: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 57: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 58: Asia Pacific Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 59: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 60: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 61: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 62: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 63: Asia Pacific Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 64: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 65: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 66: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 67: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 68: Latin America Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 69: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 70: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 71: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 72: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 73: Latin America Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 74: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2025
Figure 75: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2025
Figure 76: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Disease Indication, 2017 and 2025
Figure 77: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Route of Administration, 2017 and 2025
Figure 78: Middle East & Africa Rheumatology Therapeutics Market Value Share Analysis, by Distribution Channel, 2017 and 2025
Figure 79: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 80: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 81: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Disease Indication, 2017–2025
Figure 82: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 83: Middle East & Africa Rheumatology Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 84: Global rheumatology therapeutics Market Share, by Company, 2016

List of Tables

Table 01: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 03: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 04: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 05: Global Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 06: Global rheumatology therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 07: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 08: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 09: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 10: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 11: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: North America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 14: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 16: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 17: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 18: Europe Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 19: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 20: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 21: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 22: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 23: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Asia Pacific Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 25: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 26: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 27: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 28: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 29: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 30: Latin America Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 31: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 32: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 33: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Modifying Anti-rheumatic Drugs (DMARDs), 2015–2025
Table 34: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Disease Indication, 2015–2025
Table 35: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 36: Middle East & Africa Rheumatology Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025


 
 
Back To Top